Literature DB >> 657168

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

R T Eagan, J N Ingle, E T Creagan, S Frytak, L K Kvols, J Rubin, R T McMachon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 657168

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  15 in total

1.  Carboplatin and etoposide in advanced lung cancer:--a phase I study.

Authors:  K Liippo; V Nikkanen; E Heinonen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.

Authors:  N Niederle; J Ostermann; W Achterrath; L Lenaz; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.

Authors:  C Gridelli; R Pepe; S Palmeri; S Iacobelli; M Gentile; V Gebbia; C Garufi; G Airoma; G Palmieri; A Russo
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 4.  Combination chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma.

Authors:  A Veronesi; V Zagonel; M Santarossa; U Tirelli; E Galligioni; M G Trovo'; S Tumolo; E Grigoletto
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 6.  VP16-213 (etoposide). A critical review of its activity.

Authors:  F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 7.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.

Authors:  L Morasca; S Marsoni; M B Pisoni; E Piazza; G Vago; W Casali; R Cogo; C Bianchi; R Scapaticci
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC).

Authors:  R Chapman; L Itri; R Gralla; D Kelsen; E Casper; R Golbey
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 10.  Update in cancer chemotherapy, Part III: Lung cancer, Part 1.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-10       Impact factor: 1.798
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.